4D Molecular Therapeutics FDMT Insider Ownership

Updated Oct 16, 2026

Over the past year, FDMT insiders sold $5.38 million of stock (430.23K shares) on the open market and bought none.

• Counted by insider, open-market selling of FDMT stock in the past 12 months came from 3 insiders, with no insider buying.
• David Kirn (Director and officer) was FDMT's largest open-market seller in the past 12 months, with $5.01 million of sales (400K shares); the latest was on October 5, 2026.
• Beyond open-market trades, insiders at 4D Molecular Therapeutics acquired 89.36K shares through option exercises and conversions in the last 12 months.
• According to Business Quant data, insiders at 4D Molecular Therapeutics reported 6.06Mn shares in total in their latest Form 4 filings, down 3.71% from 6.29Mn shares at the end of Q2 2026.
• Of the 6.06Mn shares held by 4D Molecular Therapeutics insiders, 895.46K shares (14.78%) are held directly and 5.16Mn shares (85.22%) indirectly, through trusts, partnerships, family members and other entities.
• The insider holdings in 4D Molecular Therapeutics belong to 7 insiders who have reported on Form 4 within the past two years.
• FDMT's largest insider holders by reported holdings are Ra Capital Management, L.P. (10% owner, 4.56Mn shares), David Kirn (Director and officer, 1.31Mn shares) and BVF Partners L.P. (87.91K shares).
• Ra Capital Management, L.P. alone accounts for 75.32% of the shares held by 4D Molecular Therapeutics insiders.
• Institutional holders reported 82.61% of 4D Molecular Therapeutics' outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 8.62%, and other investors, including the public, hold the remaining 8.77%.
• Over the past 12 months, 12 insiders reported transactions in 4D Molecular Therapeutics stock in 32 Form 4 filings.
• These insider figures for 4D Molecular Therapeutics are based on Form 4 filings through October 7, 2026.